| Active ingredients | Dosage form | Quantity of active ingredients | Shortage status | Availability | Reason | Last updated |
| fentanyl | Drug delivery system, transdermal | 4.2 mg | Discontinued | Unavailable | Manufacturing | 16/05/2025 |
| fentanyl | Drug delivery system, transdermal | 8.4 mg | Discontinued | Unavailable | Manufacturing | 16/05/2025 |
| fentanyl | Drug delivery system, transdermal | 12.6 mg | Discontinued | Unavailable | Manufacturing | 16/05/2025 |
| fentanyl | Drug delivery system, transdermal | 16.8 mg | Discontinued | Unavailable | Manufacturing | 16/05/2025 |
| fentanyl | Drug delivery system, transdermal | 2.1 mg | Discontinued | Unavailable | Manufacturing | 16/05/2025 |
| calcitonin salmon | Injection, solution | 100 IU/mL | Current | Limited Availability | Commercial Changes / Commercial viability | 16/05/2025 |
| furosemide | Injection, solution | 20 mg | Resolved | Available | Manufacturing | 16/05/2025 |
| silver sulfadiazine | Cream | 10 mg/g | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 16/05/2025 |
| silver sulfadiazine | Cream | 10 mg/g | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 16/05/2025 |
| fentanyl | Drug delivery system, transdermal | 5.1 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 16/05/2025 |
| fentanyl | Drug delivery system, transdermal | 7.65 mg | Discontinued | Unavailable | Commercial Changes / Commercial viability | 16/05/2025 |
| fentanyl | Drug delivery system, transdermal | 1.28 mg | Discontinued | Unavailable | Commercial Changes / Commercial viability | 16/05/2025 |
| fentanyl | Drug delivery system, transdermal | 10.2 mg | Discontinued | Unavailable | Commercial Changes / Commercial viability | 16/05/2025 |
| fentanyl | Drug delivery system, transdermal | 2.55 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 16/05/2025 |
| carboplatin | Injection, solution | 450 mg | Anticipated | Available | Manufacturing | 16/05/2025 |
| dulaglutide | Injection, solution | 1.5 mg | Current | Limited Availability | Manufacturing | 16/05/2025 |
| busulfan | Injection, concentrated | 60 mg | Current | Limited Availability | Manufacturing | 16/05/2025 |
| isavuconazonium sulfate | Capsule, hard | 186.3 mg | Resolved | Available | Manufacturing | 16/05/2025 |
| buprenorphine hydrochloride | Tablet, uncoated | .216 mg | Anticipated | Available | Manufacturing | 16/05/2025 |
| lidocaine hydrochloride | Injection, solution | 10 mg/mL | Current | Unavailable | Manufacturing | 16/05/2025 |
| paclitaxel | Injection, concentrated | 6 mg/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 16/05/2025 |
| iopromide | Injection, solution | 498.72 mg/mL | Resolved | Available | Manufacturing | 16/05/2025 |
| voriconazole | Tablet, film coated | 50 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 16/05/2025 |
| sertraline hydrochloride | Tablet, film coated | 112 mg | Anticipated | Available | Manufacturing | 16/05/2025 |
| ceftazidime pentahydrate | Injection, powder for | 2.328 g | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 15/05/2025 |
| sumatriptan succinate | Tablet, film coated | 140 mg | Resolved | Available | Manufacturing | 15/05/2025 |
| bethanechol chloride | Tablet, uncoated | 10 mg | Anticipated | Available | Manufacturing | 15/05/2025 |
| galantamine hydrobromide | Capsule, modified release | 20.512 mg | Current | Limited Availability | Manufacturing | 15/05/2025 |
| methylphenidate hydrochloride | Capsule, modified release | 10 mg | Current | Limited Availability | Manufacturing | 15/05/2025 |
| valsartan~hydrochlorothiazide | Tablet, film coated | 160 mg~12.5 mg | Current | Limited Availability | Manufacturing | 15/05/2025 |
| amlodipine besilate~atorvastatin calcium trihydrate | Tablet, film coated | 6.94 mg~43.376 mg | Anticipated | Available | Manufacturing | 15/05/2025 |
| rosuvastatin calcium~ezetimibe | Tablet~Tablet, film coated | 10.396 mg~10 mg | Resolved | Available | Manufacturing | 15/05/2025 |
| imatinib mesilate | Capsule, hard | 119.47 mg | Resolved | Available | Manufacturing | 15/05/2025 |
| mercaptopurine monohydrate | Tablet | 50 mg | Current | Limited Availability | Manufacturing | 15/05/2025 |
| topotecan hydrochloride | Injection, concentrated | 4.346 mg | Resolved | Available | Manufacturing | 15/05/2025 |
| irinotecan hydrochloride trihydrate | Injection, concentrated | 500 mg | Resolved | Available | Manufacturing | 15/05/2025 |
| metoprolol tartrate | Tablet, uncoated | 50 mg | Current | Limited Availability | Manufacturing | 15/05/2025 |
| foscarnet sodium | Injection, solution | 24 mg/mL | Current | Limited Availability | Manufacturing | 15/05/2025 |
| bleomycin sulfate | Injection, powder for | 15000 IU | Anticipated | Available | Manufacturing | 15/05/2025 |
| trandolapril | Capsule, hard | 2 mg | Anticipated | Available | Manufacturing | 15/05/2025 |
| losartan potassium | Tablet, film coated | 50 mg | Current | Limited Availability | Unexpected increase in consumer demand | 15/05/2025 |
| voriconazole | Injection, powder for | 200 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 15/05/2025 |
| sertraline hydrochloride | Tablet, film coated | 56 mg | Anticipated | Available | Manufacturing | 15/05/2025 |
| Mumps virus~Rubella virus~Measles virus | Injection, powder for | 5000 CCID50~1000 CCID50~1000 CCID50 | Anticipated | Available | Unexpected increase in consumer demand | 15/05/2025 |
| fentanyl | Drug delivery system, transdermal | 16.8 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 14/05/2025 |
| honey bee venom | Injection, powder for | 550 microgram | Current | Limited Availability | Manufacturing | 14/05/2025 |
| perindopril erbumine | Tablet | 8 mg | Current | Limited Availability | Manufacturing | 14/05/2025 |
| Paper wasp venom | Injection, powder for | 550 microgram | Current | Unavailable | Manufacturing | 14/05/2025 |
| lansoprazole | Tablet, orally disintegrating | 15 mg | Current | Limited Availability | Manufacturing | 14/05/2025 |
| celecoxib | Capsule, hard | 200 mg | Current | Limited Availability | Manufacturing | 14/05/2025 |
| entecavir | Tablet, film coated | .5 mg | Current | Unavailable | Manufacturing | 14/05/2025 |
| cisatracurium besilate | Injection, solution | 14.07 mg | Current | Limited Availability | Manufacturing | 14/05/2025 |
| procarbazine hydrochloride | Capsule, hard | 58.3 mg | Resolved | Available | Manufacturing | 14/05/2025 |
| atomoxetine hydrochloride | Capsule, hard | 91.44 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 14/05/2025 |
| olanzapine | Tablet, uncoated | 5 mg | Resolved | Available | Manufacturing | 14/05/2025 |
| dosulepin hydrochloride | Capsule, hard | 25 mg | Resolved | Available | Manufacturing | 14/05/2025 |
| methylphenidate hydrochloride | Capsule, hard | 40 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 14/05/2025 |
| methylphenidate hydrochloride | Capsule, hard | 30 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 14/05/2025 |
| methylphenidate hydrochloride | Capsule, hard | 10 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 14/05/2025 |
| fentanyl citrate | Injection, solution | 785 microgram | Current | Limited Availability | Manufacturing | 14/05/2025 |
| tamoxifen citrate | Tablet, uncoated | 15.2 mg | Current | Unavailable | Manufacturing | 14/05/2025 |
| tamoxifen citrate | Tablet, uncoated | 30.4 mg | Current | Limited Availability | Manufacturing | 14/05/2025 |
| gemfibrozil | Tablet, film coated | 600 mg | Current | Unavailable | Manufacturing | 14/05/2025 |
| mirtazapine | Tablet, film coated | 30 mg | Resolved | Available | Manufacturing | 14/05/2025 |
| trimethoprim~sulfamethoxazole | Tablet | 160 mg~800 mg | Resolved | Available | Unexpected increase in consumer demand | 13/05/2025 |
| pramipexole dihydrochloride monohydrate | Tablet | .25 mg | Anticipated | Available | Manufacturing | 13/05/2025 |
| phenobarbital sodium | Injection, solution | 219 mg/mL | Anticipated | Available | Manufacturing | 13/05/2025 |
| galantamine hydrobromide | Capsule, modified release | 10.252 mg | Current | Unavailable | Manufacturing | 13/05/2025 |
| galantamine hydrobromide | Capsule, modified release | 20.504 mg | Current | Unavailable | Manufacturing | 13/05/2025 |
| ondansetron | Tablet, orally disintegrating | 8 mg | Current | Unavailable | Manufacturing | 13/05/2025 |
| raloxifene hydrochloride | Tablet, film coated | 60 mg | Resolved | Available | Unexpected increase in consumer demand | 13/05/2025 |
| dutasteride | Capsule, soft | 500 microgram | Current | Limited Availability | Manufacturing | 13/05/2025 |
| capecitabine | Tablet, film coated | 500 mg | Current | Limited Availability | Unexpected increase in consumer demand | 13/05/2025 |
| methotrexate | Injection, solution | 100 mg/mL | Current | Unavailable | Manufacturing | 13/05/2025 |
| pramipexole dihydrochloride monohydrate | Tablet, modified release | .375 mg | Current | Limited Availability | Manufacturing | 13/05/2025 |
| linezolid | Tablet, film coated | 600 mg | Current | Unavailable | Manufacturing | 13/05/2025 |
| irbesartan | Tablet, film coated | 300 mg | Anticipated | Available | Manufacturing | 13/05/2025 |
| irbesartan | Tablet, film coated | 150 mg | Anticipated | Available | Manufacturing | 13/05/2025 |
| nizatidine | Capsule, hard | 150 mg | Current | Unavailable | Manufacturing | 13/05/2025 |
| moxonidine | Tablet, film coated | 200 microgram | Current | Limited Availability | Manufacturing | 13/05/2025 |
| ropinirole hydrochloride | Tablet, film coated | .57 mg | Resolved | Available | Manufacturing | 13/05/2025 |
| risperidone | Tablet, film coated | 3 mg | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 13/05/2025 |
| atorvastatin calcium trihydrate~ezetimibe | Tablet, film coated | 41.363 mg~10 mg | Current | Unavailable | Manufacturing | 13/05/2025 |
| suxamethonium chloride dihydrate | Injection, solution | 100 mg | Anticipated | Available | Manufacturing | 13/05/2025 |
| methotrexate | Tablet | 10 mg | Resolved | Available | Manufacturing | 13/05/2025 |
| azithromycin dihydrate | Tablet, film coated | 524 mg | Current | Unavailable | Unexpected increase in consumer demand | 13/05/2025 |
| rivaroxaban | Tablet, film coated | 20 mg | Current | Limited Availability | Manufacturing | 13/05/2025 |
| metoclopramide hydrochloride monohydrate | Injection, solution | 10.54 mg | Anticipated | Available | Unexpected increase in consumer demand | 13/05/2025 |
| midazolam | Injection, solution | 5 mg/mL | Current | Limited Availability | Unexpected increase in consumer demand | 13/05/2025 |
| Teriparatide | Injection, solution | 250 microgram | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 13/05/2025 |
| metformin hydrochloride | Tablet, film coated | 1000 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 13/05/2025 |
| Peginterferon alfa2a | Injection, solution | 180 microgram | Current | Limited Availability | Unexpected increase in consumer demand | 13/05/2025 |
| heparin sodium | Injection, solution | 5000 IU/mL | Resolved | Available | Unexpected increase in consumer demand | 12/05/2025 |
| exemestane | Tablet, film coated | 25 mg | Current | Unavailable | Manufacturing | 12/05/2025 |
| aripiprazole | Tablet, uncoated | 10 mg | Current | Limited Availability | Manufacturing | 12/05/2025 |
| sulfamethoxazole~trimethoprim | Tablet, uncoated | 800 mg~160 mg | Current | Limited Availability | Manufacturing | 12/05/2025 |
| montelukast sodium | Tablet, chewable | 4.16 mg | Anticipated | Available | Manufacturing | 12/05/2025 |
| quetiapine fumarate | Tablet, modified release | 57.565 mg | Current | Unavailable | Unexpected increase in consumer demand | 12/05/2025 |
| zolmitriptan | Tablet, film coated | 2.5 mg | Current | Unavailable | Manufacturing | 12/05/2025 |
| zolmitriptan | Tablet, film coated | 2.5 mg | Current | Unavailable | Manufacturing | 12/05/2025 |
| adrenaline (epinephrine) acid tartrate | Injection, solution | 182 microgram/mL | Current | Unavailable | Manufacturing | 12/05/2025 |
| estradiol~dydrogesterone | Tablet, film coated | 1 mg~10 mg | Resolved | Available | Manufacturing | 12/05/2025 |
| ezetimibe | Tablet, uncoated | 10 mg | Resolved | Available | Manufacturing | 12/05/2025 |
| olmesartan medoxomil~hydrochlorothiazide | Tablet | 40 mg~25 mg | Resolved | Available | Manufacturing | 12/05/2025 |
| acamprosate calcium | Tablet, enteric coated | 333 mg | Current | Limited Availability | Manufacturing | 12/05/2025 |
| avibactam sodium~ceftazidime pentahydrate | Injection, powder for | 543.5 mg~2329.7 mg | Current | Limited Availability | Unexpected increase in consumer demand | 12/05/2025 |
| sitagliptin hydrochloride monohydrate | Tablet, film coated | 54.5 mg | Resolved | Available | Manufacturing | 12/05/2025 |
2025年5月19日